arrow_back Back to App

Reauthorizing Opioid Programs, Expanding Medicaid Access, and Combating Xylazine

This act extends and expands programs supporting opioid use disorder prevention, treatment, and recovery. It increases funding for key services, improves access to care for pregnant women and youth, and modifies Medicaid to facilitate healthcare access for individuals with mental health conditions and substance use disorders.
Key points
Increased funding for opioid prevention and treatment programs, including for first responders and community support.
Expanded Medicaid coverage for substance use disorder and mental health treatment, including for pregnant women and foster youth.
Classification of xylazine, a substance often mixed with illicit drugs, as a controlled substance to combat its illegal trafficking.
Requirement to update guidelines for opioid overdose reversal agents to include all approved medications.
article Official text account_balance Process page
VOTING RESULTS
2023-12-12
91%
For 386
Against 37
Abstain 0
Full voting results open_in_new
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_4531
Sponsor: Rep. Guthrie, Brett [R-KY-2]
Process start date: 2023-07-11
Voting date: 2023-12-12
Meeting no: 1
Voting no: 715
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Support for Patients and Communities Reauthorization Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_4531.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-07-11.

What are the main provisions?

Key points include:

  • Increased funding for opioid prevention and treatment programs, including for first responders and community support.
  • Expanded Medicaid coverage for substance use disorder and mental health treatment, including for pregnant women and foster youth.
  • Classification of xylazine, a substance often mixed with illicit drugs, as a controlled substance to combat its illegal trafficking.
  • Requirement to update guidelines for opioid overdose reversal agents to include all approved medications.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Where is the official voting record?

The official roll call vote is recorded at: voting record

Who is the primary sponsor?

The primary sponsor is Rep. Guthrie, Brett [R-KY-2].

What is the latest detailed status?

The latest detailed status is: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 386 - 37 (Roll no. 715). (text: 12/11/2023 CR H6790-6794)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Benefits